Evidence map›Paper›PMID 33448911›Full record

ArticleVascular medicine (London, England)2021

Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.

Clemens Höbaus, Martin Ursli, Sarah Mohammed Yussef, Thomas Wrba, Renate Koppensteiner, Gerit-Holger Schernthaner

Open access · hybridAbstract read
In one paragraph

Article in Vascular medicine (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Clemens HöbausDivision of Angiology, Medicine II, Medical University Vienna, Vienna, Austria.ORCID 0000-0002-9704-1452
Martin UrsliDepartment of Internal Medicine I, University Hospital of St Poelten, Karl Landsteiner University of Health Sciences, Karl Landsteiner Institute for Nephrology and Hematooncology, St Poelten, Austria.
Sarah Mohammed YussefDivision of Angiology, Medicine II, Medical University Vienna, Vienna, Austria.
Thomas WrbaIT4Science, IT-Systems & Communications, Medical University Vienna, Vienna, Austria.
Renate KoppensteinerDivision of Angiology, Medicine II, Medical University Vienna, Vienna, Austria.
Gerit-Holger SchernthanerDivision of Angiology, Medicine II, Medical University Vienna, Vienna, Austria.
Medical University of Vienna · ATKarl Landsteiner University of Health Sciences · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soluble urokinase-type plasminogen activator receptor (suPAR) is associated with chronic kidney disease (CKD) severity and peripheral artery disease (PAD). We hypothesize an association of PAD severity and suPAR in patients without advanced CKD and further risk stratification according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. For study purposes, suPAR was measured in 334 PAD patients (34% women, age 69 (62-78) years, eGFR 68 ± 20 mL/min/1.72 m

Indexed as

Peripheral Arterial DiseaseAgedBiomarkersErbB ReceptorsFemaleHumansKidneyMaleMiddle AgedPatient AcuityReceptors, Urokinase Plasminogen ActivatorRenal Insufficiency, ChronicBiomarkersErbB ReceptorsReceptors, Urokinase Plasminogen Activatoratherosclerosischronic kidney disease (CKD)mortalityperipheral artery disease (PAD)soluble urokinase-type plasminogen activator receptor (suPAR)

Identifiers

PMID33448911
PMCPMC7879231
OpenAlexW3123218808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.